Summary of trials performed or underway in paediatric ulcerative colitis for medications within this review
| Medication | Historical trial data | Planned/ongoing trials |
| Infliximab | IFX Kids (open-label phase 3) | |
| Adalimumab | ENVISION I (RCT) | |
| Golimumab | GOLI Kids (open label) | |
| Vedolizumab | HUBBLE (phase 2) | |
| Ustekinumab | None | A Study of Ustekinumab in Paediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)- NCT04630028 |
| Mirikizumab | None | A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)- NCT04004611 |
| Tofacitinib | None | Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis- NCT04624230 |
| Upadacitinib | None | Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Paediatric Participants With Moderately to Severely Active Ulcerative Colitis- NCT05782907 |
| Ozanimod/etrasimod | None | A Study Investigating Oral Ozanimod (RPC1063) in Paediatric Participants With Moderate to Severe Active Ulcerative Colitis- NCT05076175 |